Related Experiment Videos
[Idiopathic retroperitoneal fibrosis. Pitfalls and challenges--experience with two cases]
Hajnal Székely1, Krisztina Hagymási, Zoltán Sápi
1Semmelweis Egyetem, Általános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest, Szentkirályi u. 46. 1088.
Orvosi Hetilap
|October 21, 2011
Summary
Retroperitoneal fibrosis, a chronic inflammation of the retroperitoneum, often presents with nonspecific symptoms, complicating diagnosis. Treatment involves immunosuppression, typically with corticosteroids, but optimal use and relapse prediction remain unclear.
Area of Science:
- Nephrology
- Rheumatology
- Pathology
Background:
- Retroperitoneal fibrosis (RPF) is a chronic, nonspecific inflammation of the retroperitoneum.
- Idiopathic cases constitute approximately 75% of RPF diagnoses.
- The exact pathomechanism of RPF is not well-defined, with autoimmune processes and secondary fibrosis suspected.
Observation:
- Nonspecific symptoms and laboratory findings complicate RPF diagnosis.
- Complications are frequently present at the time of diagnosis.
- This review examines two patient cases to highlight diagnostic challenges.
Findings:
- Autoimmune inflammation and secondary fibrosis are implicated in RPF pathogenesis, possibly triggered by an unknown factor linked to atherosclerosis.
- Current treatment strategies focus on immunosuppression, primarily using corticosteroids.
- Optimal corticosteroid dosage, treatment duration, and factors predicting treatment response, relapse, or steroid dependency are unknown.
Implications:
- Early diagnosis and management of RPF complications are crucial.
- Further research is needed to elucidate RPF pathomechanisms and identify predictive factors for treatment outcomes.
- Standardized treatment protocols and long-term follow-up strategies are essential for managing RPF and preventing relapses.
